Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Ammonio methacrylate copolymer(type B) - reference spectrum

Ammonio methacrylate copolymer(type B) - reference spectrum

NA

DISCOVER
ARGININE ASPARTATE CRS (20 MG)

ARGININE ASPARTATE CRS (20 MG)

7675-83-4

DISCOVER
ASPARAGINE MONOHYDRATE CRS (60 MG)

ASPARAGINE MONOHYDRATE CRS (60 MG)

5794-13-8

DISCOVER
AZITHROMYCIN CRS (410 MG)

AZITHROMYCIN CRS (410 MG)

117772-70-0

DISCOVER
AZITHROMYCIN IMPURITY A CRS (10 MG)

AZITHROMYCIN IMPURITY A CRS (10 MG)

NA

DISCOVER
BUMETANIDE IMPURITY A CRS (5 MG)

BUMETANIDE IMPURITY A CRS (5 MG)

NA

DISCOVER
BUMETANIDE IMPURITY B CRS (5 MG)

BUMETANIDE IMPURITY B CRS (5 MG)

NA

DISCOVER
CELIPROLOL HYDROCHLORIDE CRS (15 MG)

CELIPROLOL HYDROCHLORIDE CRS (15 MG)

57470-78-7

DISCOVER
Celiprolol impurity I CRS, 0.02mg

Celiprolol impurity I CRS, 0.02mg

NA

DISCOVER
CLOFAZIMINE CRS (80 MG)

CLOFAZIMINE CRS (80 MG)

2030-63-9

DISCOVER
ESTRADIOL FOR PEAK IDENTIFICATION CRS (15 MG)

ESTRADIOL FOR PEAK IDENTIFICATION CRS (15 MG)

50-28-2

DISCOVER
POTASSIUM HYDROGEN ASPARTATE HEMIHYDRATE CRS (50 MG)

POTASSIUM HYDROGEN ASPARTATE HEMIHYDRATE CRS (50 MG)

1115-63-5

DISCOVER